Back to BMRNView full pipeline
Approved
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
7 competitors in Achondroplasia
View Full LandscapeDrug Information
Target Indication
Achondroplasia
Mechanism of Action
C-type Natriuretic Peptide Analog
Clinical Trial
NCT03197766Last updated: 12/3/2025
Patent & Exclusivity
ActiveRLD
Latest Patent Expiry
Jul 11, 2042(15y 9m)
Patents Listed
8
Exclusivity
NCENPPODE-387ODE-449
Application
NDA 214938Regulatory Approvals
EMA8/26/2021
Voxzogo
Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinPhase 3
Phenylketonurias
MiglustatPhase 3
Pompe Disease (Late-onset)
BMN 110 - WeeklyPhase 3
Mucopolysaccharidosis IV A
Cipaglucosidase AlfaPhase 3
Pompe Disease (Late-onset)
Valoctocogene roxaparvovecPhase 3
Hemophilia A With Inhibitor
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts